BidaskClub upgraded shares of Lantheus (NASDAQ:LNTH) from a buy rating to a strong-buy rating in a research report released on Thursday morning, BidAskClub reports.

A number of other analysts have also recently commented on LNTH. Zacks Investment Research cut Lantheus from a buy rating to a hold rating in a research note on Wednesday, January 30th. ValuEngine raised Lantheus from a hold rating to a buy rating in a research note on Wednesday, February 20th. Finally, TheStreet raised Lantheus from a c+ rating to a b rating in a research note on Monday, March 4th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $23.33.

Shares of NASDAQ:LNTH opened at $23.99 on Thursday. The stock has a market cap of $965.84 million, a price-to-earnings ratio of 25.52, a PEG ratio of 1.87 and a beta of 1.52. Lantheus has a 1-year low of $12.59 and a 1-year high of $26.40. The company has a debt-to-equity ratio of 3.16, a current ratio of 4.57 and a quick ratio of 3.82.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03. The company had revenue of $86.51 million during the quarter, compared to analysts’ expectations of $86.80 million. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. As a group, sell-side analysts expect that Lantheus will post 1.11 EPS for the current year.

In related news, CEO Mary Anne Heino sold 16,827 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $23.89, for a total transaction of $401,997.03. Following the completion of the sale, the chief executive officer now directly owns 637,762 shares of the company’s stock, valued at approximately $15,236,134.18. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Brian A. Markison sold 5,000 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $24.29, for a total value of $121,450.00. Following the sale, the director now directly owns 57,467 shares of the company’s stock, valued at $1,395,873.43. The disclosure for this sale can be found here. Over the last three months, insiders have sold 134,362 shares of company stock valued at $3,290,120. 2.60% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlueMountain Capital Management LLC increased its stake in Lantheus by 87.5% during the 1st quarter. BlueMountain Capital Management LLC now owns 21,429 shares of the medical equipment provider’s stock worth $525,000 after purchasing an additional 10,003 shares in the last quarter. Jane Street Group LLC bought a new stake in Lantheus during the 1st quarter worth approximately $378,000. RMB Capital Management LLC bought a new stake in Lantheus during the 1st quarter worth approximately $333,000. Man Group plc increased its stake in Lantheus by 29.9% during the 1st quarter. Man Group plc now owns 155,393 shares of the medical equipment provider’s stock worth $3,804,000 after purchasing an additional 35,772 shares in the last quarter. Finally, C M Bidwell & Associates Ltd. bought a new stake in Lantheus during the 1st quarter worth approximately $45,000. 92.56% of the stock is owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Read More: What causes a recession?

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.